美罗培南对细菌性脑膜炎的疗效和安全性系统评价
|
摘要
目的评价美罗培南用于治疗细菌性脑膜炎时的疗效和安全性。方法以"脑膜炎"、"美罗培南""美洛培南"为关键词,在Pubmed、Cochrane library、Embase、CNKI、VIP、Wanfang数据库中检索相关文献,于纳入文献中提取所需数据后采用Rev Man5.3软件对结果进行分析。结果 (1)美罗培南治疗细菌性脑膜炎有效率与头孢类药物有统计学差异(RR=1.24,95%CI[1.11,1.39],P=0.0001);(2)美罗培南治疗细菌性脑膜炎时不良反应发生率与头孢类药物无统计学差异(RR=1.33,95%CI[0.98,1.82],P=0.07)。结论相比于头孢类药物,美罗培南由于更优的疗效及相当的安全性可以被应用于细菌性脑膜炎的治疗。
Objective To review the efficacy and safety of meropenem for the treatment of bacterial meningitis. Methods The related literatures were searched and retrieved from several primary databases, including Pubmed, Cochrane library, Embase, CNKI, VIP, and Wanfang. The extracted data were analyzed by Rev Man5.3. Results(1)The efficiency between meropenem and cephalosporin for the treatment of bacterial meningitis had statistical significance(RR=1.24, 95%CI[1.11,1.39], P=0.0001);(2)The safety between meropenem and cephalosporin for the treatment of bacterial meningitis had no statistical significance(RR=1.35, 95% CI[0.99,1.86], P=0.06). Conclusion Meropenem may be prescribed for bacterial meningitis due to its better efficiency compared with cephalosporin.
Objective To review the efficacy and safety of meropenem for the treatment of bacterial meningitis. Methods The related literatures were searched and retrieved from several primary databases, including Pubmed, Cochrane library, Embase, CNKI, VIP, and Wanfang. The extracted data were analyzed by Rev Man5.3. Results(1)The efficiency between meropenem and cephalosporin for the treatment of bacterial meningitis had statistical significance(RR=1.24, 95%CI[1.11,1.39], P=0.0001);(2)The safety between meropenem and cephalosporin for the treatment of bacterial meningitis had no statistical significance(RR=1.35, 95% CI[0.99,1.86], P=0.06). Conclusion Meropenem may be prescribed for bacterial meningitis due to its better efficiency compared with cephalosporin.
引文
[1]Sebastuaan G B,Heckenberg,Brouwer M C,et al.Handbook of Clinical Neurology[M].121(3rd series):1361.
[2]Lundbo L F,Benfield T.Risk factors for communityacquired bacterial meningitis[J].Infect Dis,2017,49(6):433-444.
[3]王柯,高亮.神经外科院内获得性细菌性脑膜炎的治疗进展[J].2015,23(6):476-479.
[4]Tunkel A R,Hasbun R,Bhimraj A,et al.2017 Infectious disease society of America clinical practice guidelines for healthcare-associated ventriculitis and meningitis[J].Clin Infect Dis,2017,64(6):701-706.
[5]Odio C M,Puig J R,Feris J M,et al.Prospective,randomized,investigator-blinded study of the efficacy and safety of meropenem vs.cefotaxime therapy in bacterial meningitis in children[J].Pediat Infect Dis J,1999,18(7):581-590.
[6]陆忠,何志高.头孢曲松(罗氏芬)治疗细菌性脑膜炎疗效的荟粹分析[J].药学实践,2009,19(1):50-52.
[7]王洪星,田洪英,张庆红.美罗培南的抗菌性研究进展[J].中国医院药学杂志,2010,30(11):963-964.
[8]杨帆.抗菌药物临床应用指导原则(2015年版)解读[J].中华临床感染病杂志,2016,9(5):390-393.
[9]Schmutzhard E,Williams K J,Vukmirovits G,et al.A randomised comparison of meropenem with cefotaxime or ceftriaone for treatment of bacterial meningitis in adults[J].J Antimicrob Chemother,1995,36:85-97.
[10]Klugman K P,Dagan R.The meropenem meningitis study group.Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis[J].Antimicrob Agents Chemother,1995,39(5):1140-1146.
[11]Odio C M,Puig J R,Feris J M,et al.Prospective,randomized,investigator-blinded study of the efficacy and safety of meropenem vs.cefotaxime therapy in bacterial meningitis in children[J].Pediat Infect Dis J,1999,18(7):581-590.
[12]相春霞,宋翠云.美罗培南治疗细菌性脑膜炎疗效观察[J].现代中西医结合杂志,2010,19(4):449-450.
[13]廖春玲.美罗培南与头孢他啶治疗化脓性脑膜炎的临床疗效观察[J].中国保健营养,2013,9(9):495.
[14]刘见民.美罗培南治疗细菌性脑膜炎疗效观察[J].中国医药科学,2014,4(6):101-103.
[15]邹娜娜.75例小儿化脓性脑膜炎的临床诊治研究75例小儿化脓性脑膜炎的临床诊治研究[J].特别健康,2014,10(10):38.
[16]高树辉,陈小强,李奕,等.新生儿化脓性脑膜炎的早期诊断与治疗效果分析[J].临床医学工程,2015,22(8):1028-1029.
[17]阿吉古丽·艾山,吾马尔江·塔瓦库力.美罗培南治疗化脓性脑膜炎患儿的临床效果[J].世界最新医学信息文摘,2017,17(53):116.
[18]张佩朵,王中标.美罗培南治疗化脓性脑膜炎的效果观察及价值评价[J].中国生化药物杂志,2017,3(37):255-257
[19]黄妮娜.美罗培南在小儿化脓性脑膜炎临床治疗中的应用分析[J].陕西医学杂志,2017,46(8):1130-1131.
[20]亓芳,朱立勤,刘薇,等.美罗培南治疗天津地区常见病原菌所致肺部感染的疗效评价[J].中国抗生素杂志,2016,41(10):792-795.
[21]谢本树.新型碳青霉烯类抗生素美罗培南的临床应用研究进展[J].中国药房,2011,22(5):456-459.
[22]Hurst M,Lamb H M.Meropenem:A review of its use in patients in intensive care[J].Drugs,2000,59(3):653-680.
[23]李志业,冀建伟,邢玲.美罗培南的神经毒性不良反应分析[J].中国实用神经疾病杂志,2016,19(15):120-121.
[2]Lundbo L F,Benfield T.Risk factors for communityacquired bacterial meningitis[J].Infect Dis,2017,49(6):433-444.
[3]王柯,高亮.神经外科院内获得性细菌性脑膜炎的治疗进展[J].2015,23(6):476-479.
[4]Tunkel A R,Hasbun R,Bhimraj A,et al.2017 Infectious disease society of America clinical practice guidelines for healthcare-associated ventriculitis and meningitis[J].Clin Infect Dis,2017,64(6):701-706.
[5]Odio C M,Puig J R,Feris J M,et al.Prospective,randomized,investigator-blinded study of the efficacy and safety of meropenem vs.cefotaxime therapy in bacterial meningitis in children[J].Pediat Infect Dis J,1999,18(7):581-590.
[6]陆忠,何志高.头孢曲松(罗氏芬)治疗细菌性脑膜炎疗效的荟粹分析[J].药学实践,2009,19(1):50-52.
[7]王洪星,田洪英,张庆红.美罗培南的抗菌性研究进展[J].中国医院药学杂志,2010,30(11):963-964.
[8]杨帆.抗菌药物临床应用指导原则(2015年版)解读[J].中华临床感染病杂志,2016,9(5):390-393.
[9]Schmutzhard E,Williams K J,Vukmirovits G,et al.A randomised comparison of meropenem with cefotaxime or ceftriaone for treatment of bacterial meningitis in adults[J].J Antimicrob Chemother,1995,36:85-97.
[10]Klugman K P,Dagan R.The meropenem meningitis study group.Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis[J].Antimicrob Agents Chemother,1995,39(5):1140-1146.
[11]Odio C M,Puig J R,Feris J M,et al.Prospective,randomized,investigator-blinded study of the efficacy and safety of meropenem vs.cefotaxime therapy in bacterial meningitis in children[J].Pediat Infect Dis J,1999,18(7):581-590.
[12]相春霞,宋翠云.美罗培南治疗细菌性脑膜炎疗效观察[J].现代中西医结合杂志,2010,19(4):449-450.
[13]廖春玲.美罗培南与头孢他啶治疗化脓性脑膜炎的临床疗效观察[J].中国保健营养,2013,9(9):495.
[14]刘见民.美罗培南治疗细菌性脑膜炎疗效观察[J].中国医药科学,2014,4(6):101-103.
[15]邹娜娜.75例小儿化脓性脑膜炎的临床诊治研究75例小儿化脓性脑膜炎的临床诊治研究[J].特别健康,2014,10(10):38.
[16]高树辉,陈小强,李奕,等.新生儿化脓性脑膜炎的早期诊断与治疗效果分析[J].临床医学工程,2015,22(8):1028-1029.
[17]阿吉古丽·艾山,吾马尔江·塔瓦库力.美罗培南治疗化脓性脑膜炎患儿的临床效果[J].世界最新医学信息文摘,2017,17(53):116.
[18]张佩朵,王中标.美罗培南治疗化脓性脑膜炎的效果观察及价值评价[J].中国生化药物杂志,2017,3(37):255-257
[19]黄妮娜.美罗培南在小儿化脓性脑膜炎临床治疗中的应用分析[J].陕西医学杂志,2017,46(8):1130-1131.
[20]亓芳,朱立勤,刘薇,等.美罗培南治疗天津地区常见病原菌所致肺部感染的疗效评价[J].中国抗生素杂志,2016,41(10):792-795.
[21]谢本树.新型碳青霉烯类抗生素美罗培南的临床应用研究进展[J].中国药房,2011,22(5):456-459.
[22]Hurst M,Lamb H M.Meropenem:A review of its use in patients in intensive care[J].Drugs,2000,59(3):653-680.
[23]李志业,冀建伟,邢玲.美罗培南的神经毒性不良反应分析[J].中国实用神经疾病杂志,2016,19(15):120-121.